D-PLEX₁₀₀ has received Breakthrough Therapy Designation, three QIDP designations, and three Fast Track designations from the U.S. Food and Drug Administration. NDA submission is expected early 2026.
D-PLEX100 has received Breakthrough Therapy Designation, three QIDP designations, and three Fast Track designations from the U.S. Food and Drug Administration. NDA submission is expected early 2026.
NDA Meeting with the FDA Scheduled for Early December; NDA Submission for D-PLEX₁₀₀ On Track for Early 2026 Advancements in Discussions with Potential U.S. Partners Following Positive Phase 3 Trial ...
Bhangu, J. , Sweetman, S. , Williams, G. and Shuttleworth, G. (2025) Patient Footwear Contamination in Ophthalmic Day Surgery: A Prospective Observational Study. International Journal of Clinical ...
Face-to-Face Pre-NDA Meeting with the FDA Scheduled for Early December; NDA Submission for D-PLEX100 On Track for Early 2026 Advancements in Discussions with Potential U.S. Partners Following Positive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback